Related Experiment Video
Updated: Mar 29, 2026
A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform
Published on: July 16, 2016
MiR-577 inhibits pancreatic β-cell function and survival by targeting fibroblast growth factor 21 (FGF-21) in
Abstract:
Pancreatic β-cell dysfunction is a central component of the pathogenesis of pediatric diabetes. MicroRNA (miRNA) have become one of the most encouraging and fruitful fields in biological research, and have been implicated as new players in the pathogenesis of diabetes and diabetes-associated complications. The role of miRNA in diabetes begins with the development of pancreatic islets. Fibroblast growth factor (FGF)-21 enhances glucose uptake in adipocytes, protecting transgenic animals from diet-induced obesity when overexpressed, and lowers blood glucose and triglyceride levels in diabetic animals (when administered); therefore, it is a good way to treat diabetes. However, the mechanism of miRNA in regulation of FGF21 is not known. In this study, FGF-21 was predicted to be the target of miR-577. Therefore, we investigated the effects of miR-577 on β-cell function and survival by targeting FGF-21. We demonstrated that, although FGF-21 does not acutely stimulate insulin secretion in isolated islets from normal rats, it increases insulin secretion and insulin content in diabetic islets and protects β-cells from apoptosis via the activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways.
Insights
MicroRNA-577 targets Fibroblast Growth Factor-21 to improve pancreatic beta-cell function and survival in diabetes. This study reveals a novel mechanism for regulating beta-cell health and offers potential therapeutic strategies for diabetes treatment.
Area of Science:
- Endocrinology
- Molecular Biology
- Genetics
Background:
- Pancreatic beta-cell dysfunction is central to pediatric diabetes pathogenesis.
- MicroRNAs (miRNAs) are increasingly recognized for their role in diabetes and its complications.
- Fibroblast Growth Factor-21 (FGF-21) shows therapeutic potential for diabetes but its miRNA regulation is unknown.
Purpose of the Study:
- To investigate the effect of miR-577 on pancreatic beta-cell function and survival.
- To determine if miR-577 targets FGF-21 and mediates its effects on beta-cells.
Main Methods:
- Prediction of miR-577 as a target of FGF-21.
- Experimental investigation of miR-577's effects on beta-cell function and apoptosis.
- Analysis of extracellular signal-regulated kinase 1/2 (ERK1/2) and Akt signaling pathways.
Main Results:
- FGF-21 does not acutely stimulate insulin secretion in normal rat islets.
- miR-577 targeting of FGF-21 increased insulin secretion and content in diabetic islets.
- miR-577 protected beta-cells from apoptosis through ERK1/2 and Akt pathway activation.
Conclusions:
- miR-577 plays a crucial role in regulating pancreatic beta-cell function and survival by targeting FGF-21.
- The findings elucidate a novel miRNA-mediated mechanism in diabetes pathogenesis.
- Targeting the miR-577/FGF-21 axis presents a potential therapeutic avenue for diabetes.
